Positron emission tomography/computed tomography in the management of Hodgkin and B‐cell non‐Hodgkin lymphoma: An update

18F‐fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is now an integral part of lymphoma staging and management. Because of its greater accuracy compared with CT alone, PET/CT is currently routinely performed for staging and for response assessment at the end of tre...

Full description

Saved in:
Bibliographic Details
Published inCancer Vol. 127; no. 20; pp. 3727 - 3741
Main Authors Juweid, Malik E., Mueller, Marguerite, Alhouri, Abdullah, A‐Risheq, M. Ziad, Mottaghy, Felix M.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 15.10.2021
Subjects
Chemotherapy
Classification
Computed tomography
Deauville 5‐point scale
diffuse large B‐cell lymphoma
end‐of‐treatment positron emission tomography/computed tomography
Fluorodeoxyglucose F18
follicular lymphoma
Glycolysis
Hodgkin lymphoma
Humans
interim positron emission tomography/computed tomography
Lugano classification
Lymphoma
Lymphoma - therapy
Lymphoma, Non-Hodgkin - therapy
Non-Hodgkin's lymphoma
non‐Hodgkin lymphoma
Oncology
Positron emission
Positron emission tomography
Positron Emission Tomography Computed Tomography - methods
positron emission tomography/computed tomography (PET/CT)
Precision medicine
Prognosis
Radiation
response‐adapted treatment
Tomography
Tumor Burden
Deauville 5-point scale
follicular lymphoma
Lugano classification
positron emission tomography/computed tomography (PET/CT)
non-Hodgkin lymphoma
response-adapted treatment
diffuse large B-cell lymphoma
end-of-treatment positron emission tomography/computed tomography
interim positron emission tomography/computed tomography
Hodgkin lymphoma
Online AccessGet full text

Cover

Abstract 18F‐fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is now an integral part of lymphoma staging and management. Because of its greater accuracy compared with CT alone, PET/CT is currently routinely performed for staging and for response assessment at the end of treatment in the vast majority of FDG‐avid lymphomas and is the cornerstone of response classification for these lymphomas according to the Lugano classification. Interim PET/CT, typically performed after 2 to 4 of 6 to 8 chemotherapy/chemoimmunotherapy cycles with or without radiation, is commonly performed for prognostication and potential treatment escalation or de‐escalation early in the course of therapy, a concept known as response‐adapted or risk‐adapted treatment. Quantitative PET is an area of growing interest. Metrics, such as the standardized uptake value, changes (Δ) in the standardized uptake value, metabolic tumor volume, and total lesion glycolysis, are being investigated as more reproducible and potentially more accurate predictors of response and prognosis. Despite the progress made in standardizing the use of PET/CT in lymphoma, challenges remain, particularly with respect to its limited positive predictive value, emphasizing the need for more specific molecular probes. This review highlights the most relevant applications of PET/CT in Hodgkin and B‐cell non‐Hodgkin lymphoma, its strengths and limitations, as well as recent efforts at implementing PET/CT‐based metrics as promising tools for precision medicine. This review highlights the most relevant applications of positron emission tomography/computed tomography in lymphoma, their strengths and limitations, and recent efforts at implementing positron emission tomography‐based and computed tomography‐based metrics as potential tools of precision medicine in lymphoma.
AbstractList 18F‐fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is now an integral part of lymphoma staging and management. Because of its greater accuracy compared with CT alone, PET/CT is currently routinely performed for staging and for response assessment at the end of treatment in the vast majority of FDG‐avid lymphomas and is the cornerstone of response classification for these lymphomas according to the Lugano classification. Interim PET/CT, typically performed after 2 to 4 of 6 to 8 chemotherapy/chemoimmunotherapy cycles with or without radiation, is commonly performed for prognostication and potential treatment escalation or de‐escalation early in the course of therapy, a concept known as response‐adapted or risk‐adapted treatment. Quantitative PET is an area of growing interest. Metrics, such as the standardized uptake value, changes (Δ) in the standardized uptake value, metabolic tumor volume, and total lesion glycolysis, are being investigated as more reproducible and potentially more accurate predictors of response and prognosis. Despite the progress made in standardizing the use of PET/CT in lymphoma, challenges remain, particularly with respect to its limited positive predictive value, emphasizing the need for more specific molecular probes. This review highlights the most relevant applications of PET/CT in Hodgkin and B‐cell non‐Hodgkin lymphoma, its strengths and limitations, as well as recent efforts at implementing PET/CT‐based metrics as promising tools for precision medicine.
18 F‐fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is now an integral part of lymphoma staging and management. Because of its greater accuracy compared with CT alone, PET/CT is currently routinely performed for staging and for response assessment at the end of treatment in the vast majority of FDG‐avid lymphomas and is the cornerstone of response classification for these lymphomas according to the Lugano classification. Interim PET/CT, typically performed after 2 to 4 of 6 to 8 chemotherapy/chemoimmunotherapy cycles with or without radiation, is commonly performed for prognostication and potential treatment escalation or de‐escalation early in the course of therapy, a concept known as response‐adapted or risk‐adapted treatment. Quantitative PET is an area of growing interest. Metrics, such as the standardized uptake value, changes (Δ) in the standardized uptake value, metabolic tumor volume, and total lesion glycolysis, are being investigated as more reproducible and potentially more accurate predictors of response and prognosis. Despite the progress made in standardizing the use of PET/CT in lymphoma, challenges remain, particularly with respect to its limited positive predictive value, emphasizing the need for more specific molecular probes. This review highlights the most relevant applications of PET/CT in Hodgkin and B‐cell non‐Hodgkin lymphoma, its strengths and limitations, as well as recent efforts at implementing PET/CT‐based metrics as promising tools for precision medicine. This review highlights the most relevant applications of positron emission tomography/computed tomography in lymphoma, their strengths and limitations, and recent efforts at implementing positron emission tomography‐based and computed tomography‐based metrics as potential tools of precision medicine in lymphoma.
18F‐fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is now an integral part of lymphoma staging and management. Because of its greater accuracy compared with CT alone, PET/CT is currently routinely performed for staging and for response assessment at the end of treatment in the vast majority of FDG‐avid lymphomas and is the cornerstone of response classification for these lymphomas according to the Lugano classification. Interim PET/CT, typically performed after 2 to 4 of 6 to 8 chemotherapy/chemoimmunotherapy cycles with or without radiation, is commonly performed for prognostication and potential treatment escalation or de‐escalation early in the course of therapy, a concept known as response‐adapted or risk‐adapted treatment. Quantitative PET is an area of growing interest. Metrics, such as the standardized uptake value, changes (Δ) in the standardized uptake value, metabolic tumor volume, and total lesion glycolysis, are being investigated as more reproducible and potentially more accurate predictors of response and prognosis. Despite the progress made in standardizing the use of PET/CT in lymphoma, challenges remain, particularly with respect to its limited positive predictive value, emphasizing the need for more specific molecular probes. This review highlights the most relevant applications of PET/CT in Hodgkin and B‐cell non‐Hodgkin lymphoma, its strengths and limitations, as well as recent efforts at implementing PET/CT‐based metrics as promising tools for precision medicine. This review highlights the most relevant applications of positron emission tomography/computed tomography in lymphoma, their strengths and limitations, and recent efforts at implementing positron emission tomography‐based and computed tomography‐based metrics as potential tools of precision medicine in lymphoma.
F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is now an integral part of lymphoma staging and management. Because of its greater accuracy compared with CT alone, PET/CT is currently routinely performed for staging and for response assessment at the end of treatment in the vast majority of FDG-avid lymphomas and is the cornerstone of response classification for these lymphomas according to the Lugano classification. Interim PET/CT, typically performed after 2 to 4 of 6 to 8 chemotherapy/chemoimmunotherapy cycles with or without radiation, is commonly performed for prognostication and potential treatment escalation or de-escalation early in the course of therapy, a concept known as response-adapted or risk-adapted treatment. Quantitative PET is an area of growing interest. Metrics, such as the standardized uptake value, changes (Δ) in the standardized uptake value, metabolic tumor volume, and total lesion glycolysis, are being investigated as more reproducible and potentially more accurate predictors of response and prognosis. Despite the progress made in standardizing the use of PET/CT in lymphoma, challenges remain, particularly with respect to its limited positive predictive value, emphasizing the need for more specific molecular probes. This review highlights the most relevant applications of PET/CT in Hodgkin and B-cell non-Hodgkin lymphoma, its strengths and limitations, as well as recent efforts at implementing PET/CT-based metrics as promising tools for precision medicine.
Author Juweid, Malik E.
Alhouri, Abdullah
Mottaghy, Felix M.
A‐Risheq, M. Ziad
Mueller, Marguerite
Author_xml – sequence: 1
  givenname: Malik E.
  orcidid: 0000-0002-6294-8118
  surname: Juweid
  fullname: Juweid, Malik E.
  email: mjuweid@yahoo.com
  organization: University of Jordan
– sequence: 2
  givenname: Marguerite
  surname: Mueller
  fullname: Mueller, Marguerite
  organization: Aachen University
– sequence: 3
  givenname: Abdullah
  surname: Alhouri
  fullname: Alhouri, Abdullah
  organization: University of Jordan
– sequence: 4
  givenname: M. Ziad
  surname: A‐Risheq
  fullname: A‐Risheq, M. Ziad
  organization: University of Jordan
– sequence: 5
  givenname: Felix M.
  surname: Mottaghy
  fullname: Mottaghy, Felix M.
  organization: Maastricht University Medical Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34286864$$D View this record in MEDLINE/PubMed
BookMark eNp9kctKxDAYhYMoOl42PoAE3IhQzaVtUnfj4A1ERRTclZgmM9UmqUmLDLjwEXxGn8SMoyIuXP23j8P5Oatg0TqrANjEaA8jRPallX6PUsbIAhhgVLAE4ZQsggFCiCdZSu9WwGoID3FkJKPLYIWmhOc8Twfg5cqFuvPOQmXqEOrYdM64sRftZLovnWn7TlW_drCOxERBI6wYK6NsB52Gp64aP8aLsBU8fH99k6ppYLQZ2-9TMzXtxBlxAIcW9m0lOrUOlrRogtr4qmvg9vjoZnSanF-enI2G54mkBSVJmiJEdY4LyaiQBb4XQmksCM9ypmmqq4JmWKpKYs4ZSomknEmNOCl4rkn8eA3szHVb7556Fboy_jqzKKxyfShJllFOMMtpRLf_oA-u9za6ixTLc1agjEdqd05J70LwSpetr43w0xKjcpZJOcuk_Mwkwltfkv29UdUP-h1CBPAceK4bNf1HqhxdjK7noh9OWpsB
CitedBy_id crossref_primary_10_1055_a_1675_3441
crossref_primary_10_29235_1814_6023_2023_20_1_7_16
crossref_primary_10_1021_cbmi_3c00024
crossref_primary_10_1186_s43055_024_01247_6
crossref_primary_10_1007_s00277_023_05138_0
crossref_primary_10_1097_MNM_0000000000001846
crossref_primary_10_1038_s41598_024_58412_0
crossref_primary_10_2174_1389557523666230915103121
crossref_primary_10_1053_j_semnuclmed_2022_11_001
crossref_primary_10_2147_OTT_S440228
crossref_primary_10_3389_fendo_2023_1266721
crossref_primary_10_47582_jompac_1350661
crossref_primary_10_3390_jcm11195541
crossref_primary_10_1038_s41598_022_22032_3
Cites_doi 10.1007/s00259-010-1490-5
10.1182/blood-2015-11-679407
10.1097/RCT.0000000000000067
10.1002/hon.2438_45
10.1002/cncr.23861
10.1093/annonc/mdh426
10.1097/RLU.0b013e318217aeff
10.1007/s00259-008-1021-9
10.1016/j.ejca.2010.12.027
10.1200/JCO.2005.01.891
10.1056/NEJMra050276
10.1182/blood.V98.10.2930
10.1055/s-0038-1623988
10.1200/JCO.2006.08.2305
10.1200/JCO.2007.11.6525
10.1182/blood.V126.23.815.815
10.1007/s00259-018-4171-4
10.1002/1097-0142(20010301)91:5<889::AID-CNCR1078>3.0.CO;2-5
10.1200/JCO.2013.51.7524
10.1080/028418699432969
10.1093/annonc/8.suppl_1.S57
10.1007/s00277-001-0390-y
10.1200/JCO.2014.58.9846
10.1007/s13139-015-0368-7
10.1200/JCO.2015.63.0699
10.1111/bjh.16014
10.3109/10428194.2013.831848
10.1023/A:1008486928190
10.1007/s00259-020-05080-7
10.1182/blood-2014-10-606939
10.1200/JCO.2005.12.072
10.1007/s00259-014-2961-x
10.1016/S0002-9343(01)01117-2
10.3109/10428194.2011.593273
10.1200/JCO.2012.42.4036
10.1200/JCO.2001.19.2.414
10.1200/JCO.2005.01.904
10.1016/S0140-6736(11)61940-5
10.1056/NEJMoa1408648
10.1182/blood.V124.21.392.392
10.2967/jnumed.107.046292
10.1200/JCO.2013.51.9298
10.1182/blood-2007-06-097238
10.1200/JCO.2013.54.8800
10.1002/cncr.21967
10.1111/bjh.13389
10.1016/S1470-2045(15)70013-6
10.1200/JCO.1988.6.6.931
10.1007/s00259-014-2822-7
10.1023/A:1008381115131
10.1148/radiol.2323030985
10.1200/JCO.2012.45.5402
10.1182/blood-2013-11-536169
10.1182/blood-2005-06-2252
10.1007/s00259-013-2435-6
10.1182/blood.V94.2.429
10.1093/annonc/mdw011
10.1182/blood.V91.9.3340
10.1200/JCO.2013.53.5229
10.1007/s002590050275
10.1200/JCO.2006.09.2403
10.1038/sj.bmt.1705416
10.1200/JCO.2009.22.4089
10.1093/annonc/mdp030
10.1007/s11307-009-0259-3
10.1182/blood-2017-04-773838
10.1023/A:1008327127033
10.1053/j.semnuclmed.2019.06.005
10.1046/j.1365-2141.2001.03147.x
10.1093/annonc/mdg011
10.1200/JCO.2011.38.2648
10.1157/13112510
10.1200/JCO.2016.66.9440
10.3109/10428190009113384
10.1182/blood-2011-06-359943
10.1097/MNM.0000000000000697
10.1016/S1078-8174(99)90024-X
10.1200/JCO.2012.43.0934
10.1007/s00259-016-3390-9
10.1007/s00277-010-1135-6
10.1080/10428194.2019.1663422
10.1007/s11547-008-0264-7
10.1007/s00259-003-1375-y
10.3109/10428194.2011.616613
10.2967/jnumed.110.082586
10.1016/j.bbmt.2008.11.026
10.1182/blood-2016-05-716977
10.1007/s00259-006-0238-8
10.1002/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4
10.2967/jnumed.120.242412
10.1016/j.ymeth.2020.06.020
10.1093/annonc/mdn282
10.3816/CLM.2008.n.040
10.1200/JCO.2009.26.5942
10.1182/blood-2016-05-718528
10.2967/jnumed.114.145326
10.1007/s00277-012-1640-x
10.1016/j.ymeth.2020.05.022
10.1007/s00259-010-1539-5
10.1093/annonc/mdq428
10.1111/ejh.12268
10.1093/annonc/mdi200
10.1111/ejh.12467
10.1007/s00259-011-1916-8
10.3109/10428194.2013.767901
10.2967/jnumed.112.110890
10.1038/nrclinonc.2017.141
10.1007/s00259-009-1377-5
10.1182/blood-2017-02-766691
10.1182/blood.V124.21.391.391
10.1182/blood-2017-07-795476
10.1093/annonc/mdj024
10.1182/blood-2012-12-473389
10.1182/blood-2011-02-336990
10.1007/s12149-016-1092-9
10.1182/asheducation-2006.1.259
10.1093/annonc/mdt137
10.1007/s00259-009-1297-4
10.1046/j.1365-2141.2001.03169.x
10.1023/A:1008368330519
10.1016/j.ijrobp.2007.09.051
10.1111/j.1365-2141.2010.08162.x
10.1007/s00259-016-3315-7
10.1148/radiol.2015150689
10.1038/sj.bjc.6601561
10.2967/jnumed.109.073197
10.18632/oncotarget.20447
10.1200/JCO.1999.17.4.1244
10.1007/s00277-007-0356-9
10.1056/NEJMoa1510093
10.3109/10428194.2015.1099643
10.1016/j.ejrad.2020.109301
10.1182/blood-2017-06-788877
10.1111/bjh.13036
10.3109/10428194.2013.862242
10.1002/cncr.25579
10.1023/A:1008357126404
10.1007/s00259-014-2715-9
ContentType Journal Article
Copyright 2021 American Cancer Society
2021 American Cancer Society.
Copyright_xml – notice: 2021 American Cancer Society
– notice: 2021 American Cancer Society.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TO
7U7
C1K
H94
K9.
NAPCQ
7X8
DOI 10.1002/cncr.33772
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Oncogenes and Growth Factors Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Oncogenes and Growth Factors Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList AIDS and Cancer Research Abstracts
CrossRef

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-0142
EndPage 3741
ExternalDocumentID 10_1002_cncr_33772
34286864
CNCR33772
Genre reviewArticle
Journal Article
Review
GroupedDBID ---
-~X
.3N
.GA
05W
0R~
10A
1CY
1L6
1OC
24P
29B
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
6J9
6P2
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
85S
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AARRQ
AAWTL
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABHFT
ABIJN
ABIVO
ABJNI
ABLJU
ABOCM
ABPPZ
ABPVW
ABQWH
ABXGK
ACAHQ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACNCT
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEIGN
AEIMD
AENEX
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AIACR
AIAGR
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
E3Z
EBS
EMOBN
EX3
F00
F01
F04
F5P
FD6
FUBAC
G-S
G.N
GNP
GODZA
GX1
H.X
HBH
HGLYW
HHY
HHZ
HZ~
IH2
IX1
J0M
JPC
KBYEO
KQQ
KZ1
L7B
LATKE
LAW
LC2
LC3
LH4
LITHE
LMP
LOXES
LP6
LP7
LSO
LUTES
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
QRW
R.K
ROL
RWI
RX1
RYL
SJN
SUPJJ
TEORI
UDS
UHB
V2E
V8K
V9Y
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WIN
WJL
WOHZO
WQJ
WRC
WVDHM
WXI
WXSBR
XG1
XPP
XV2
Z0Y
ZGI
ZZTAW
~IA
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TO
7U7
C1K
H94
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c3932-44003f619c73ac91baaef1a28567f34fd9351cedc1887042c387cf082986f2253
IEDL.DBID DR2
ISSN 0008-543X
IngestDate Sat Aug 17 01:06:12 EDT 2024
Tue Oct 15 22:38:22 EDT 2024
Fri Aug 23 01:41:05 EDT 2024
Sat Sep 28 08:22:07 EDT 2024
Sat Aug 24 00:59:56 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 20
Keywords Deauville 5-point scale
follicular lymphoma
Lugano classification
positron emission tomography/computed tomography (PET/CT)
non-Hodgkin lymphoma
response-adapted treatment
diffuse large B-cell lymphoma
end-of-treatment positron emission tomography/computed tomography
interim positron emission tomography/computed tomography
Hodgkin lymphoma
Language English
License 2021 American Cancer Society.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3932-44003f619c73ac91baaef1a28567f34fd9351cedc1887042c387cf082986f2253
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ORCID 0000-0002-6294-8118
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.33772
PMID 34286864
PQID 2576679058
PQPubID 2045183
PageCount 15
ParticipantIDs proquest_miscellaneous_2553821763
proquest_journals_2576679058
crossref_primary_10_1002_cncr_33772
pubmed_primary_34286864
wiley_primary_10_1002_cncr_33772_CNCR33772
PublicationCentury 2000
PublicationDate October 15, 2021
PublicationDateYYYYMMDD 2021-10-15
PublicationDate_xml – month: 10
  year: 2021
  text: October 15, 2021
  day: 15
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Atlanta
PublicationTitle Cancer
PublicationTitleAlternate Cancer
PublicationYear 2021
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2010; 12
2011; 118
2011; 117
2006; 38
2011; 52
2013; 122
2011; 55
2016; 30
2001; 40
2016; 34
1997; 8
2015; 372
2004; 31
2013; 54
2010; 28
2000; 11
2016; 43
2006; 2006
1998; 91
2008; 113
2012; 379
2009; 15
2014; 123
2014; 124
2021; 48
2010; 37
2015; 126
2015; 125
2013; 92
2002; 81
2017; 130
2012; 39
2014; 41
2016; 280
2006; 354
2012; 30
2019; 187
2011; 90
2019; 46
1999; 38
2008; 49
2006; 47
2014; 38
2019; 49
2007; 86
2005; 16
2006; 107
2016; 27
2021; 62
2010; 51
2012; 119
2014; 32
1998; 9
2001; 91
2017; 8
2013; 24
2020; 61
2015; 33
2002; 112
2003; 14
2008; 8
2008; 71
2007; 34
2005; 23
2012; 53
2001; 86
2018; 131
2015; 170
2017; 38
1999; 17
2015; 42
2017; 35
2001; 19
2011; 22
1999; 10
2010; 150
2020; 133
1999; 94
2001; 12
2007; 25
2014; 55
2014; 167
2001; 98
2006; 91
2007; 129
2014; 92
2015; 16
2009; 20
2015; 94
2013; 40
2006; 17
2008; 19
2016; 50
2016; 128
2016; 127
2021; 188
2011; 36
2004; 90
1999; 5
2009; 27
2016; 57
1998; 25
2004; 232
2009; 36
2000; 39
2017; 14
2007; 110
1988; 6
2004; 15
2001; 8
2016; 374
2011; 47
2001; 115
e_1_2_12_6_1
e_1_2_12_130_1
e_1_2_12_2_1
Dittmann H (e_1_2_12_72_1) 2001; 8
e_1_2_12_111_1
e_1_2_12_138_1
e_1_2_12_115_1
e_1_2_12_134_1
e_1_2_12_108_1
e_1_2_12_20_1
e_1_2_12_66_1
e_1_2_12_43_1
e_1_2_12_85_1
e_1_2_12_47_1
e_1_2_12_89_1
e_1_2_12_62_1
e_1_2_12_81_1
e_1_2_12_100_1
e_1_2_12_123_1
e_1_2_12_146_1
e_1_2_12_28_1
e_1_2_12_104_1
e_1_2_12_142_1
e_1_2_12_31_1
e_1_2_12_77_1
e_1_2_12_54_1
e_1_2_12_96_1
e_1_2_12_139_1
Hutchings M (e_1_2_12_24_1) 2006; 91
e_1_2_12_35_1
Pelosi E (e_1_2_12_58_1) 2011; 55
Hertzberg MS (e_1_2_12_91_1) 2015; 126
e_1_2_12_12_1
e_1_2_12_73_1
e_1_2_12_92_1
e_1_2_12_3_1
e_1_2_12_18_1
Fan Y (e_1_2_12_127_1) 2016; 57
e_1_2_12_110_1
e_1_2_12_137_1
e_1_2_12_114_1
e_1_2_12_133_1
e_1_2_12_21_1
e_1_2_12_44_1
e_1_2_12_63_1
e_1_2_12_86_1
e_1_2_12_107_1
e_1_2_12_25_1
e_1_2_12_48_1
e_1_2_12_67_1
e_1_2_12_40_1
e_1_2_12_82_1
e_1_2_12_141_1
e_1_2_12_29_1
Jerusalem G (e_1_2_12_17_1) 2001; 86
e_1_2_12_126_1
e_1_2_12_103_1
e_1_2_12_145_1
e_1_2_12_119_1
e_1_2_12_32_1
e_1_2_12_55_1
e_1_2_12_74_1
e_1_2_12_97_1
e_1_2_12_36_1
e_1_2_12_59_1
e_1_2_12_78_1
e_1_2_12_13_1
e_1_2_12_7_1
e_1_2_12_51_1
e_1_2_12_70_1
e_1_2_12_93_1
e_1_2_12_4_1
e_1_2_12_19_1
e_1_2_12_38_1
e_1_2_12_136_1
e_1_2_12_132_1
e_1_2_12_113_1
e_1_2_12_41_1
e_1_2_12_87_1
e_1_2_12_106_1
e_1_2_12_129_1
e_1_2_12_22_1
e_1_2_12_64_1
e_1_2_12_45_1
e_1_2_12_26_1
e_1_2_12_68_1
Rodriguez‐Vigil B (e_1_2_12_50_1) 2006; 47
e_1_2_12_83_1
e_1_2_12_60_1
e_1_2_12_140_1
e_1_2_12_49_1
e_1_2_12_121_1
e_1_2_12_102_1
e_1_2_12_125_1
e_1_2_12_144_1
e_1_2_12_52_1
e_1_2_12_98_1
e_1_2_12_118_1
e_1_2_12_33_1
e_1_2_12_75_1
e_1_2_12_56_1
e_1_2_12_37_1
e_1_2_12_79_1
Bruzzi JF (e_1_2_12_122_1) 2006; 47
e_1_2_12_14_1
e_1_2_12_90_1
e_1_2_12_8_1
e_1_2_12_10_1
e_1_2_12_94_1
e_1_2_12_71_1
e_1_2_12_5_1
e_1_2_12_16_1
e_1_2_12_112_1
e_1_2_12_135_1
e_1_2_12_39_1
e_1_2_12_116_1
e_1_2_12_131_1
e_1_2_12_42_1
e_1_2_12_65_1
e_1_2_12_88_1
e_1_2_12_109_1
e_1_2_12_128_1
e_1_2_12_23_1
e_1_2_12_46_1
e_1_2_12_69_1
e_1_2_12_80_1
e_1_2_12_61_1
e_1_2_12_84_1
e_1_2_12_27_1
Zijlstra JM (e_1_2_12_76_1) 2006; 91
e_1_2_12_101_1
e_1_2_12_147_1
e_1_2_12_120_1
e_1_2_12_105_1
e_1_2_12_143_1
e_1_2_12_124_1
e_1_2_12_30_1
e_1_2_12_53_1
e_1_2_12_99_1
e_1_2_12_117_1
e_1_2_12_34_1
e_1_2_12_57_1
e_1_2_12_15_1
e_1_2_12_11_1
e_1_2_12_95_1
e_1_2_12_9_1
References_xml – volume: 50
  start-page: 46
  year: 2016
  end-page: 53
  article-title: FDG PET/CT response assessment criteria for patients with Hodgkin's and non‐Hodgkin's lymphoma at end of therapy: a multiparametric approach
  publication-title: Nucl Med Mol Imaging
– volume: 49
  start-page: 438
  year: 2019
  end-page: 449
  article-title: Radiomics analysis for clinical decision support in nuclear medicine
  publication-title: Semin Nucl Med
– volume: 131
  start-page: 84
  year: 2018
  end-page: 94
  article-title: Reclassifying patients with early‐stage Hodgkin lymphoma based on functional radiographic markers at presentation
  publication-title: Blood
– volume: 94
  start-page: 429
  year: 1999
  end-page: 433
  article-title: Whole‐body positron emission tomography using 18F‐fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non‐Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
  publication-title: Blood
– volume: 187
  start-page: 39
  year: 2019
  end-page: 48
  article-title: Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group
  publication-title: Br J Haematol
– volume: 27
  start-page: 719
  year: 2016
  end-page: 724
  article-title: Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG‐PET/CT in patients with peripheral T‐cell lymphoma (PTCL)
  publication-title: Ann Oncol
– volume: 25
  start-page: 571
  year: 2007
  end-page: 578
  article-title: Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
  publication-title: J Clin Oncol
– volume: 24
  start-page: 2108
  year: 2013
  end-page: 2112
  article-title: The use of FDG‐PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi
  publication-title: Ann Oncol
– volume: 43
  start-page: 1209
  year: 2016
  end-page: 1219
  article-title: Combination of baseline metabolic tumour volume and early response on PET/CT improves progression‐free survival prediction in DLBCL
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 38
  start-page: 620
  year: 2014
  end-page: 625
  article-title: Can full‐dose contrast‐enhanced CT be omitted from an FDG‐PET/CT staging examination in newly diagnosed FDG‐avid lymphoma?
  publication-title: J Comput Assist Tomogr
– volume: 43
  start-page: 1837
  year: 2016
  end-page: 1848
  article-title: Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville criteria (DC) and the International Harmonization Project criteria (IHPC)
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 62
  start-page: 30
  year: 2021
  end-page: 36
  article-title: Deep learning FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B‐cell lymphoma
  publication-title: J Nucl Med
– volume: 39
  start-page: 4
  year: 2012
  end-page: 12
  article-title: Early interim 18 F‐FDG PET in Hodgkin's lymphoma: evaluation on 304 patients
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 5
  start-page: 155
  year: 1999
  end-page: 163
  article-title: Role for whole body FDG‐PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment
  publication-title: Radiography
– volume: 47
  start-page: 1643
  year: 2006
  end-page: 1648
  article-title: PET/CT in lymphoma: prospective study of enhanced full‐dose PET/CT versus unenhanced low‐dose PET/CT
  publication-title: J Nucl Med
– volume: 37
  start-page: 1095
  year: 2010
  end-page: 1105
  article-title: (18)F‐FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 91
  start-page: 302
  year: 2001
  end-page: 310
  article-title: Whole body positron emission tomography in the treatment of Hodgkin disease
  publication-title: Cancer
– volume: 8
  start-page: 57
  issue: suppl 1
  year: 1997
  end-page: 60
  article-title: Whole‐body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma
  publication-title: Ann Oncol
– volume: 25
  start-page: 721
  year: 1998
  end-page: 728
  article-title: Whole‐body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography
  publication-title: Eur J Nucl Med
– volume: 55
  start-page: 773
  year: 2014
  end-page: 780
  article-title: Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B‐cell lymphoma
  publication-title: Leuk Lymphoma
– volume: 91
  start-page: 482
  year: 2006
  end-page: 489
  article-title: Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma
  publication-title: Haematologica
– volume: 86
  start-page: 266
  year: 2001
  end-page: 273
  article-title: Whole‐body positron emission tomography using 18F‐fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease
  publication-title: Haematologica
– volume: 90
  start-page: 620
  year: 2004
  end-page: 625
  article-title: Substantial impact of FDG PET imaging on the therapy decision in patients with early‐stage Hodgkin's lymphoma
  publication-title: Br J Cancer
– volume: 12
  start-page: 225
  year: 2010
  end-page: 232
  article-title: On the added value of baseline FDG‐PET in malignant lymphoma
  publication-title: Mol Imaging Biol
– volume: 15
  start-page: 242
  year: 2009
  end-page: 248
  article-title: Phase II study of risk‐adapted therapy of newly diagnosed, aggressive non‐Hodgkin lymphoma based on midtreatment FDG‐PET scanning
  publication-title: Biol Blood Marrow Transplant
– volume: 113
  start-page: 2496
  year: 2008
  end-page: 2503
  article-title: Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B‐cell non‐Hodgkin lymphoma
  publication-title: Cancer
– volume: 27
  start-page: 2739
  year: 2009
  end-page: 2741
  article-title: Development and application of a real‐time on‐line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials
  publication-title: J Clin Oncol
– volume: 188
  start-page: 105
  year: 2021
  end-page: 111
  article-title: Functional imaging using radiomic features in assessment of lymphoma
  publication-title: Methods
– volume: 81
  start-page: 20
  year: 2002
  end-page: 25
  article-title: Whole‐body positron emission tomography using 18F‐fluorodeoxyglucose for initial staging of patients with Hodgkin's disease
  publication-title: Ann Hematol
– volume: 28
  start-page: 1896
  year: 2010
  end-page: 1903
  article-title: Risk‐adapted dose‐dense immunochemotherapy determined by interim FDG‐PET in advanced‐stage diffuse large B‐cell lymphoma
  publication-title: J Clin Oncol
– volume: 11
  start-page: 1273
  year: 2000
  end-page: 1280
  article-title: 2‐Fluorine‐18‐fluoro‐2‐deoxy‐D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution
  publication-title: Ann Oncol
– volume: 354
  start-page: 496
  year: 2006
  end-page: 507
  article-title: Positron‐emission tomography and assessment of cancer therapy
  publication-title: N Engl J Med
– volume: 23
  start-page: 4577
  year: 2005
  end-page: 4580
  article-title: Role of positron emission tomography in lymphoma
  publication-title: J Clin Oncol
– volume: 6
  start-page: 931
  year: 1988
  end-page: 933
  article-title: Residual mass in lymphoma may not be residual disease
  publication-title: J Clin Oncol
– volume: 38
  start-page: 563
  year: 2017
  end-page: 576
  article-title: Usual and unusual pitfalls of 18F‐FDG‐PET/CT in lymphoma after treatment: a pictorial review
  publication-title: Nucl Med Commun
– volume: 150
  start-page: 39
  year: 2010
  end-page: 45
  article-title: Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre‐transplant FDG‐PET scan following salvage chemotherapy
  publication-title: Br J Haematol
– volume: 126
  start-page: 815
  year: 2015
  article-title: Early treatment intensification with R‐ICE chemotherapy followed by autologous stem cell transplantation (ASCT) using Zevalin‐BEAM for patients with poor risk diffuse large B‐cell lymphoma (DLBCL) as identified by interim PET/CT scan performed after four cycles of R‐CHOP‐14: a multicenter phase II study of the Australasian Leukaemia Lymphoma Study Group (ALLG) [abstract]
  publication-title: Blood
– volume: 124
  start-page: 391
  year: 2014
  article-title: Positron emission tomography (PET) guided therapy of aggressive lymphomas—a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL trial) [abstract]
  publication-title: Blood
– volume: 52
  start-page: 386
  year: 2011
  end-page: 392
  article-title: 18F‐FDG PET/CT for early response assessment in diffuse large B‐cell lymphoma: poor predictive value of International Harmonization Project interpretation
  publication-title: J Nucl Med
– volume: 34
  start-page: 1376
  year: 2016
  end-page: 1385
  article-title: Interim positron emission tomography response‐adapted therapy in advanced‐stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study
  publication-title: J Clin Oncol
– volume: 127
  start-page: 1531
  year: 2016
  end-page: 1538
  article-title: PET‐CT for staging and early response: results from the Response‐Adapted Therapy in Advanced Hodgkin Lymphoma Study
  publication-title: Blood
– volume: 17
  year: 1999
  article-title: Report of an international workshop to standardize response criteria for non‐Hodgkin's lymphomas
  publication-title: J Clin Oncol
– volume: 38
  start-page: 211
  year: 2006
  end-page: 216
  article-title: Prognostic value of FDG‐PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation
  publication-title: Bone Marrow Transplant
– volume: 12
  start-page: 29
  year: 2001
  end-page: 37
  article-title: 18FDG‐PET following treatment as valid predictor for disease‐free survival in Hodgkin's lymphoma
  publication-title: Ann Oncol
– volume: 14
  start-page: 123
  year: 2003
  end-page: 130
  article-title: Early detection of relapse by whole‐body positron emission tomography in the follow‐up of patients with Hodgkin's disease
  publication-title: Ann Oncol
– volume: 55
  start-page: 1936
  year: 2014
  end-page: 1944
  article-title: Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B‐cell lymphoma
  publication-title: J Nucl Med
– volume: 128
  start-page: 2199
  year: 2016
  end-page: 2205
  article-title: Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real‐world experience
  publication-title: Blood
– volume: 170
  start-page: 56
  year: 2015
  end-page: 65
  article-title: Response‐adapted therapy for aggressive non‐Hodgkin's lymphomas based on early [18F] FDG‐PET scanning: ECOG‐ACRIN Cancer Research Group study (E3404)
  publication-title: Br J Haematol
– volume: 2006
  start-page: 259
  year: 2006
  end-page: 265
  article-title: Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma
  publication-title: Hematol Am Soc Hematol Educ Program
– volume: 113
  start-page: 578
  year: 2008
  end-page: 590
  article-title: Role of whole‐body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG‐PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non‐Hodgkin lymphoma
  publication-title: Radiol Med
– volume: 32
  start-page: 3059
  year: 2014
  end-page: 3068
  article-title: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non‐Hodgkin lymphoma: the Lugano classification
  publication-title: J Clin Oncol
– volume: 91
  start-page: 3340
  year: 1998
  end-page: 3346
  article-title: Detection of lymphoma in bone marrow by whole‐body positron emission tomography
  publication-title: Blood
– volume: 30
  start-page: 4317
  year: 2012
  end-page: 4322
  article-title: Impact of [(18)F] fluorodeoxyglucose positron emission tomography response evaluation in patients with high‐tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS
  publication-title: J Clin Oncol
– volume: 92
  start-page: 471
  year: 2013
  end-page: 479
  article-title: Interim PET/CT‐based prognostic model for the treatment of diffuse large B cell lymphoma in the post‐rituximab era
  publication-title: Ann Hematol
– volume: 19
  start-page: 414
  year: 2001
  end-page: 419
  article-title: Prognostic value of positron emission tomography (PET) with fluorine‐18 fluorodeoxyglucose ([18F]FDG) after first‐line chemotherapy in non‐Hodgkin's lymphoma: is [18F]FDG‐PET a valid alternative to conventional diagnostic methods?
  publication-title: J Clin Oncol
– volume: 39
  start-page: 543
  year: 2000
  end-page: 553
  article-title: 18‐FDG‐PET as a prognostic indicator in the treatment of aggressive non‐Hodgkin's lymphoma—comparison with CT
  publication-title: Leuk Lymphoma
– volume: 90
  start-page: 797
  year: 2011
  end-page: 802
  article-title: Limited role of interim PET/CT in patients with diffuse large B‐cell lymphoma treated with R‐CHOP
  publication-title: Ann Hematol
– volume: 17
  start-page: 117
  year: 2006
  end-page: 122
  article-title: Is CT scan still necessary for staging in Hodgkin and non‐Hodgkin lymphoma patients in the PET/CT era?
  publication-title: Ann Oncol
– volume: 36
  start-page: 745
  year: 2009
  end-page: 750
  article-title: Bone marrow involvement in diffuse large B‐cell lymphoma: correlation between FDG‐PET uptake and type of cellular infiltrate
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 19
  start-page: 1770
  year: 2008
  end-page: 1773
  article-title: Combined PET and low‐dose, noncontrast CT scanning obviates the need for additional diagnostic contrast‐enhanced CT scans in patients undergoing staging or restaging for lymphoma
  publication-title: Ann Oncol
– volume: 16
  start-page: 1160
  year: 2005
  end-page: 1168
  article-title: Prognostic value of interim FDG‐PET after two or three cycles of chemotherapy in Hodgkin lymphoma
  publication-title: Ann Oncol
– volume: 232
  start-page: 823
  year: 2004
  end-page: 829
  article-title: Non‐Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging—do we need contrast‐enhanced CT?
  publication-title: Radiology
– volume: 30
  start-page: 184
  year: 2012
  end-page: 190
  article-title: Interim [18F] fluorodeoxyglucose positron emission tomography scan in diffuse large B‐cell lymphoma treated with anthracycline‐based chemotherapy plus rituximab
  publication-title: J Clin Oncol
– volume: 123
  start-page: 2783
  year: 2014
  end-page: 2790
  article-title: Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia
  publication-title: Blood
– volume: 30
  start-page: 4456
  year: 2012
  end-page: 4457
  article-title: Hodgkin lymphoma: protecting the victims of our success
  publication-title: J Clin Oncol
– volume: 379
  start-page: 1791
  year: 2012
  end-page: 1799
  article-title: Reduced‐intensity chemotherapy and PET‐guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open‐label, phase 3 non‐inferiority trial
  publication-title: Lancet
– volume: 49
  start-page: 9
  year: 2008
  end-page: 12
  article-title: 18F‐FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non‐Hodgkin's lymphoma: where is the evidence?
  publication-title: J Nucl Med
– volume: 37
  start-page: 1824
  year: 2010
  end-page: 1833
  article-title: Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 91
  start-page: 889
  year: 2001
  end-page: 899
  article-title: 2‐(Fluorine‐18) fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphoma: a bicenter trial
  publication-title: Cancer
– volume: 280
  start-page: 220
  year: 2016
  end-page: 222
  article-title: Diffuse large B‐cell lymphoma: prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST criteria for early therapeutic monitoring
  publication-title: Radiology
– volume: 35
  start-page: 184
  issue: suppl 2
  year: 2017
  end-page: 185
  article-title: End of treatment PET‐CT predicts progression‐free survival in DLBCL after first‐line treatment: results from the phase III GOYA study
  publication-title: Hematol Oncol
– volume: 30
  start-page: 588
  year: 2016
  end-page: 592
  article-title: Interim FDG‐PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET)
  publication-title: Ann Nucl Med
– volume: 51
  start-page: 1337
  year: 2010
  end-page: 1343
  article-title: 18F‐FDG PET after 2 cycles of ABVD predicts event‐free survival in early and advanced Hodgkin lymphoma
  publication-title: J Nucl Med
– volume: 372
  start-page: 1598
  year: 2015
  end-page: 1607
  article-title: Results of a trial of PET‐directed therapy for early‐stage Hodgkin's lymphoma
  publication-title: N Engl J Med
– volume: 118
  start-page: 4053
  year: 2011
  end-page: 4061
  article-title: Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B‐cell lymphoma
  publication-title: Blood
– volume: 98
  start-page: 2930
  year: 2001
  end-page: 2934
  article-title: Thoracic positron emission tomography using 18F‐fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
  publication-title: Blood
– volume: 55
  start-page: 469
  year: 2011
  end-page: 475
  article-title: Bone marrow disease detection with FDG‐PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study
  publication-title: Q J Nucl Med Mol Imaging
– volume: 71
  start-page: 213
  year: 2008
  end-page: 219
  article-title: Impact of [18F] fluorodeoxyglucose positron emission tomography on staging and management of early‐stage follicular non‐Hodgkin lymphoma
  publication-title: Int J Radiat Oncol Biol Phys
– volume: 40
  start-page: 1312
  year: 2013
  end-page: 1320
  article-title: An international confirmatory study of the prognostic value of early PET/CT in diffuse large B‐cell lymphoma: comparison between Deauville criteria and ΔSUVmax
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 117
  start-page: 1010
  year: 2011
  end-page: 1018
  article-title: Midtreatment 18F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma
  publication-title: Cancer
– volume: 122
  start-page: 61
  year: 2013
  end-page: 67
  article-title: PET‐CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement
  publication-title: Blood
– volume: 10
  start-page: 1181
  year: 1999
  end-page: 1184
  article-title: The role of positron emission tomography (PET) in the management of lymphoma patients
  publication-title: Ann Oncol
– volume: 130
  start-page: 1315
  year: 2017
  end-page: 1326
  article-title: FDG‐PET‐driven consolidation strategy in diffuse large B‐cell lymphoma: final results of a randomized phase 2 study
  publication-title: Blood
– volume: 37
  start-page: 2307
  year: 2010
  end-page: 2314
  article-title: Diagnostic and prognostic impact of 18F‐FDG PET/CT in follicular lymphoma
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 86
  start-page: 897
  year: 2007
  end-page: 903
  article-title: Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi
  publication-title: Ann Hematol
– volume: 47
  start-page: 1267
  year: 2006
  end-page: 1273
  article-title: Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT
  publication-title: J Nucl Med
– volume: 14
  start-page: 749
  year: 2017
  end-page: 762
  article-title: Radiomics: the bridge between medical imaging and personalized medicine
  publication-title: Nat Rev Clin Oncol
– volume: 55
  start-page: 2064
  year: 2014
  end-page: 2070
  article-title: Results of a prospective phase II trial evaluating interim positron emission tomography‐guided high dose therapy for poor prognosis diffuse large B‐cell lymphoma
  publication-title: Leuk Lymphoma
– volume: 11
  start-page: 147
  issue: suppl 1
  year: 2000
  end-page: 150
  article-title: 18‐FDG‐PET for the assessment of residual masses on CT following treatment of lymphomas
  publication-title: Ann Oncol
– volume: 124
  start-page: 392
  year: 2014
  article-title: Phase 2 trial of interim PET scan‐tailored therapy in patients with advanced stage diffuse large B‐cell lymphoma (DLBCL) in British Columbia (BC) [abstract]
  publication-title: Blood
– volume: 54
  start-page: 2163
  year: 2013
  end-page: 2167
  article-title: 18F‐fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma
  publication-title: Leuk Lymphoma
– volume: 16
  start-page: 284
  year: 2015
  end-page: 292
  article-title: PET‐adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non‐randomised, open‐label, single‐centre, phase 2 study
  publication-title: Lancet Oncol
– volume: 23
  start-page: 4652
  year: 2005
  end-page: 4661
  article-title: Response assessment of aggressive non‐Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine‐18–fluorodeoxyglucose positron emission tomography
  publication-title: J Clin Oncol
– volume: 107
  start-page: 52
  year: 2006
  end-page: 59
  article-title: FDG‐PET after two cycles of chemotherapy predicts treatment failure and progression‐free survival in Hodgkin lymphoma
  publication-title: Blood
– volume: 37
  start-page: 181
  year: 2010
  end-page: 200
  article-title: FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 33
  start-page: 2523
  year: 2015
  end-page: 2529
  article-title: Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B‐cell lymphoma treated with R‐CHOP‐14 (SAKK 38/07)
  publication-title: J Clin Oncol
– volume: 48
  start-page: 1362
  year: 2021
  end-page: 1370
  article-title: Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG‐PET/CT for total metabolic tumour volume prediction using a convolutional neural network
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 119
  start-page: 2066
  year: 2012
  end-page: 2073
  article-title: Interim 18‐FDG‐PET/CT failed to predict the outcome in diffuse large B‐cell lymphoma patients treated at the diagnosis with rituximab‐CHOP
  publication-title: Blood
– volume: 9
  start-page: 1117
  year: 1998
  end-page: 1122
  article-title: Whole‐body 2‐[18F]‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography (FDG‐PET) for accurate staging of Hodgkin's disease
  publication-title: Ann Oncol
– volume: 46
  start-page: 238
  year: 2019
  end-page: 250
  article-title: FDG PET/CT for assessing tumour response to immunotherapy: report on the EANM symposium on immune modulation and recent review of the literature
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 53
  start-page: 381
  year: 2012
  end-page: 385
  article-title: Routine bone marrow biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the 18F‐fluoro‐2‐deoxyglucose positron emission tomography era
  publication-title: Leuk Lymphoma
– volume: 38
  start-page: 799
  year: 1999
  end-page: 804
  article-title: Positron emission tomography with 18‐fluorodeoxyglucose in the staging and follow‐up of lymphoma in the chest
  publication-title: Acta Oncol
– volume: 34
  start-page: 60
  year: 2007
  end-page: 67
  article-title: Bone involvement in patients with lymphoma: the role of FDG‐PET/CT
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 32
  start-page: 3048
  year: 2014
  end-page: 3058
  article-title: Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group
  publication-title: J Clin Oncol
– volume: 54
  start-page: 683
  year: 2013
  end-page: 690
  article-title: International validation study for interim PET in ABVD‐treated, advanced‐stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers
  publication-title: J Nucl Med
– volume: 30
  start-page: 4508
  year: 2012
  end-page: 4514
  article-title: Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography‐staged treatment‐naive patients with Hodgkin lymphoma
  publication-title: J Clin Oncol
– volume: 115
  start-page: 793
  year: 2001
  end-page: 800
  article-title: Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma
  publication-title: Br J Haematol
– volume: 57
  start-page: 1474
  year: 2016
  end-page: 1477
  article-title: An 18F‐FDG‐PET maximum standardized uptake value >10 represents a novel valid marker for discerning Richter's syndrome
  publication-title: Leuk Lymphoma
– volume: 8
  start-page: 1393
  year: 2001
  end-page: 1399
  article-title: Comparison of 18FDG‐PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma
  publication-title: Oncol Rep
– volume: 131
  start-page: 1456
  year: 2018
  end-page: 1463
  article-title: Prognostic value of baseline metabolic tumor volume in early‐stage Hodgkin lymphoma in the standard arm of the H10 trial
  publication-title: Blood
– volume: 40
  start-page: 23
  year: 2001
  end-page: 30
  article-title: Prognostic significance of positron emission tomography using fluorine‐18‐fluorodeoxyglucose in patients treated for malignant lymphoma
  publication-title: Nuklearmedizin
– volume: 374
  start-page: 2419
  year: 2016
  end-page: 2429
  article-title: Adapted treatment guided by interim PET‐CT scan in advanced Hodgkin's lymphoma
  publication-title: N Engl J Med
– volume: 8
  start-page: 287
  year: 2008
  end-page: 293
  article-title: Value of [18F] fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?
  publication-title: Clin Lymphoma Myeloma
– volume: 20
  start-page: 1543
  year: 2009
  end-page: 1547
  article-title: High SUV uptake on FDG‐PET/CT predicts for an aggressive B‐cell lymphoma in a prospective study of primary FDG‐PET/CT staging in lymphoma
  publication-title: Ann Oncol
– volume: 15
  start-page: 1699
  year: 2004
  end-page: 1704
  article-title: Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease
  publication-title: Ann Oncol
– volume: 107
  start-page: 175
  year: 2006
  end-page: 183
  article-title: Role of fluorine‐18 fluoro‐deoxyglucose positron emission tomography scan in the evaluation and follow‐up of patients with low‐grade lymphomas
  publication-title: Cancer
– volume: 91
  start-page: 522
  year: 2006
  end-page: 529
  article-title: 18F‐fluoro‐deoxyglucose positron emission tomography for post‐treatment evaluation of malignant lymphoma: a systematic review
  publication-title: Haematologica
– volume: 133
  year: 2020
  article-title: Research on the midterm efficacy and prognosis of patients with diffuse large B‐cell lymphoma by different evaluation methods in interim PET/CT
  publication-title: Eur J Radiol
– volume: 112
  start-page: 262
  year: 2002
  end-page: 268
  article-title: Fluorine‐18 fluorodeoxyglucose positron emission tomography, gallium‐67 scintigraphy, and conventional staging for Hodgkin's disease and non‐Hodgkin's lymphoma
  publication-title: Am J Med
– volume: 94
  start-page: 532
  year: 2015
  end-page: 539
  article-title: Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole‐body volumetric‐metabolic FDG‐PET/CT metrics in diffuse large B‐cell lymphoma
  publication-title: Eur J Haematol
– volume: 167
  start-page: 327
  year: 2014
  end-page: 336
  article-title: Intensification treatment based on early FDG‐PET in patients with high‐risk diffuse large B‐cell lymphoma: a phase II GELTAMO trial
  publication-title: Br J Haematol
– volume: 110
  start-page: 3507
  year: 2007
  end-page: 3516
  article-title: The role of FDG‐PET scans in patients with lymphoma
  publication-title: Blood
– volume: 52
  start-page: 2111
  year: 2011
  end-page: 2116
  article-title: Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?
  publication-title: Leuk Lymphoma
– volume: 22
  start-page: 739
  year: 2011
  end-page: 745
  article-title: Establishment of a UK‐wide network to facilitate the acquisition of quality assured FDG‐PET data for clinical trials in lymphoma
  publication-title: Ann Oncol
– volume: 31
  start-page: 325
  year: 2004
  end-page: 329
  article-title: FDG‐PET/CT in re‐staging of patients with lymphoma
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 25
  start-page: 3746
  year: 2007
  end-page: 3752
  article-title: Early interim 2‐[18F] fluoro‐2‐deoxy‐D‐glucose positron emission tomography is prognostically superior to international prognostic score in advanced‐stage Hodgkin's lymphoma: a report from a joint Italian‐Danish study
  publication-title: J Clin Oncol
– volume: 47
  start-page: 1312
  year: 2011
  end-page: 1318
  article-title: Prognostic significance of interim [18]F‐FDG PET/CT after three or four cycles of R‐CHOP chemotherapy in the treatment of diffuse large B‐cell lymphoma
  publication-title: Eur J Cancer
– volume: 32
  start-page: 1769
  year: 2014
  end-page: 1775
  article-title: [18F] fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B‐cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG‐26 study
  publication-title: J Clin Oncol
– volume: 61
  start-page: 318
  year: 2020
  end-page: 327
  article-title: Persistent mediastinal FDG uptake on PET‐CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?
  publication-title: Leuk Lymphoma
– volume: 32
  start-page: 1188
  year: 2014
  end-page: 1194
  article-title: Omitting radiotherapy in early positron emission tomography‐negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial
  publication-title: J Clin Oncol
– volume: 41
  start-page: 2017
  year: 2014
  end-page: 2022
  article-title: Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B‐cell lymphoma
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 115
  start-page: 272
  year: 2001
  end-page: 278
  article-title: Can positron emission tomography with [(18)F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
  publication-title: Br J Haematol
– volume: 25
  start-page: 579
  year: 2007
  end-page: 586
  article-title: Revised response criteria for malignant lymphoma
  publication-title: J Clin Oncol
– volume: 128
  start-page: 2489
  year: 2016
  end-page: 2496
  article-title: Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy
  publication-title: Blood
– volume: 34
  start-page: 3618
  year: 2016
  end-page: 3626
  article-title: Baseline metabolic tumor volume predicts outcome in high‐tumor‐burden follicular lymphoma: a pooled analysis of three multicenter studies
  publication-title: J Clin Oncol
– volume: 57
  start-page: 1603
  issue: suppl 2
  year: 2016
  article-title: Evaluating early interim 18F‐FDG PET/CT with Peking criteria for predicting the outcome of diffuse large B cell lymphoma
  publication-title: J Nucl Med
– volume: 41
  start-page: 1301
  year: 2014
  end-page: 1308
  article-title: qPET—a quantitative extension of the Deauville scale to assess response in interim FDG‐PET scans in lymphoma
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 92
  start-page: 382
  year: 2014
  end-page: 389
  article-title: F‐18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B‐cell lymphoma
  publication-title: Eur J Haematol
– volume: 125
  start-page: 2579
  year: 2015
  end-page: 2581
  article-title: Prognostic value of FDG‐PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B‐cell lymphoma
  publication-title: Blood
– volume: 36
  start-page: 553
  year: 2011
  end-page: 559
  article-title: F‐18 FDG PET for evaluation of bone marrow involvement in non‐Hodgkin lymphoma: a meta‐analysis
  publication-title: Clin Nucl Med
– volume: 8
  start-page: 99587
  year: 2017
  end-page: 99600
  article-title: Prognostic significance of total metabolic tumor volume on (18)F‐fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B‐cell lymphoma receiving rituximab‐containing chemotherapy
  publication-title: Oncotarget
– volume: 130
  start-page: 2196
  year: 2017
  end-page: 2203
  article-title: Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
  publication-title: Blood
– volume: 42
  start-page: 328
  year: 2015
  end-page: 354
  article-title: FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 188
  start-page: 20
  year: 2021
  end-page: 29
  article-title: Radiomics for precision medicine: current challenges, future prospects, and the proposal of a new framework
  publication-title: Methods
– volume: 23
  start-page: 4643
  year: 2005
  end-page: 4651
  article-title: Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non‐Hodgkin's lymphoma
  publication-title: J Clin Oncol
– volume: 129
  start-page: 688
  year: 2007
  end-page: 693
  article-title: [The value of positron emission tomography/computed tomography (PET/CT) in the staging of diffuse large B‐cell lymphoma.]
  publication-title: Med Clin (Barc)
– ident: e_1_2_12_44_1
  doi: 10.1007/s00259-010-1490-5
– ident: e_1_2_12_35_1
  doi: 10.1182/blood-2015-11-679407
– ident: e_1_2_12_51_1
  doi: 10.1097/RCT.0000000000000067
– ident: e_1_2_12_77_1
  doi: 10.1002/hon.2438_45
– ident: e_1_2_12_117_1
  doi: 10.1002/cncr.23861
– ident: e_1_2_12_21_1
  doi: 10.1093/annonc/mdh426
– ident: e_1_2_12_63_1
  doi: 10.1097/RLU.0b013e318217aeff
– ident: e_1_2_12_62_1
  doi: 10.1007/s00259-008-1021-9
– ident: e_1_2_12_37_1
  doi: 10.1016/j.ejca.2010.12.027
– ident: e_1_2_12_7_1
  doi: 10.1200/JCO.2005.01.891
– ident: e_1_2_12_11_1
  doi: 10.1056/NEJMra050276
– ident: e_1_2_12_71_1
  doi: 10.1182/blood.V98.10.2930
– ident: e_1_2_12_80_1
  doi: 10.1055/s-0038-1623988
– ident: e_1_2_12_6_1
  doi: 10.1200/JCO.2006.08.2305
– ident: e_1_2_12_103_1
  doi: 10.1200/JCO.2007.11.6525
– volume: 126
  start-page: 815
  year: 2015
  ident: e_1_2_12_91_1
  article-title: Early treatment intensification with R‐ICE chemotherapy followed by autologous stem cell transplantation (ASCT) using Zevalin‐BEAM for patients with poor risk diffuse large B‐cell lymphoma (DLBCL) as identified by interim PET/CT scan performed after four cycles of R‐CHOP‐14: a multicenter phase II study of the Australasian Leukaemia Lymphoma Study Group (ALLG) [abstract]
  publication-title: Blood
  doi: 10.1182/blood.V126.23.815.815
  contributor:
    fullname: Hertzberg MS
– ident: e_1_2_12_115_1
  doi: 10.1007/s00259-018-4171-4
– ident: e_1_2_12_16_1
  doi: 10.1002/1097-0142(20010301)91:5<889::AID-CNCR1078>3.0.CO;2-5
– ident: e_1_2_12_41_1
  doi: 10.1200/JCO.2013.51.7524
– ident: e_1_2_12_67_1
  doi: 10.1080/028418699432969
– ident: e_1_2_12_64_1
  doi: 10.1093/annonc/8.suppl_1.S57
– volume: 91
  start-page: 482
  year: 2006
  ident: e_1_2_12_24_1
  article-title: Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma
  publication-title: Haematologica
  contributor:
    fullname: Hutchings M
– ident: e_1_2_12_18_1
  doi: 10.1007/s00277-001-0390-y
– ident: e_1_2_12_92_1
  doi: 10.1200/JCO.2014.58.9846
– ident: e_1_2_12_43_1
  doi: 10.1007/s13139-015-0368-7
– ident: e_1_2_12_88_1
  doi: 10.1200/JCO.2015.63.0699
– ident: e_1_2_12_90_1
  doi: 10.1111/bjh.16014
– ident: e_1_2_12_39_1
  doi: 10.3109/10428194.2013.831848
– ident: e_1_2_12_14_1
  doi: 10.1023/A:1008486928190
– ident: e_1_2_12_138_1
  doi: 10.1007/s00259-020-05080-7
– ident: e_1_2_12_119_1
  doi: 10.1182/blood-2014-10-606939
– ident: e_1_2_12_121_1
  doi: 10.1200/JCO.2005.12.072
– ident: e_1_2_12_142_1
  doi: 10.1007/s00259-014-2961-x
– ident: e_1_2_12_19_1
  doi: 10.1016/S0002-9343(01)01117-2
– ident: e_1_2_12_56_1
  doi: 10.3109/10428194.2011.593273
– ident: e_1_2_12_52_1
  doi: 10.1200/JCO.2012.42.4036
– ident: e_1_2_12_75_1
  doi: 10.1200/JCO.2001.19.2.414
– ident: e_1_2_12_8_1
  doi: 10.1200/JCO.2005.01.904
– volume: 55
  start-page: 469
  year: 2011
  ident: e_1_2_12_58_1
  article-title: Bone marrow disease detection with FDG‐PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study
  publication-title: Q J Nucl Med Mol Imaging
  contributor:
    fullname: Pelosi E
– ident: e_1_2_12_89_1
  doi: 10.1016/S0140-6736(11)61940-5
– volume: 86
  start-page: 266
  year: 2001
  ident: e_1_2_12_17_1
  article-title: Whole‐body positron emission tomography using 18F‐fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease
  publication-title: Haematologica
  contributor:
    fullname: Jerusalem G
– ident: e_1_2_12_86_1
  doi: 10.1056/NEJMoa1408648
– ident: e_1_2_12_95_1
  doi: 10.1182/blood.V124.21.392.392
– ident: e_1_2_12_12_1
  doi: 10.2967/jnumed.107.046292
– ident: e_1_2_12_87_1
  doi: 10.1200/JCO.2013.51.9298
– ident: e_1_2_12_9_1
  doi: 10.1182/blood-2007-06-097238
– ident: e_1_2_12_2_1
  doi: 10.1200/JCO.2013.54.8800
– ident: e_1_2_12_23_1
  doi: 10.1002/cncr.21967
– ident: e_1_2_12_97_1
  doi: 10.1111/bjh.13389
– ident: e_1_2_12_120_1
  doi: 10.1016/S1470-2045(15)70013-6
– ident: e_1_2_12_13_1
  doi: 10.1200/JCO.1988.6.6.931
– ident: e_1_2_12_135_1
  doi: 10.1007/s00259-014-2822-7
– ident: e_1_2_12_68_1
  doi: 10.1023/A:1008381115131
– ident: e_1_2_12_22_1
  doi: 10.1148/radiol.2323030985
– ident: e_1_2_12_59_1
  doi: 10.1200/JCO.2012.45.5402
– ident: e_1_2_12_123_1
  doi: 10.1182/blood-2013-11-536169
– ident: e_1_2_12_102_1
  doi: 10.1182/blood-2005-06-2252
– ident: e_1_2_12_38_1
  doi: 10.1007/s00259-013-2435-6
– ident: e_1_2_12_65_1
  doi: 10.1182/blood.V94.2.429
– volume: 57
  start-page: 1603
  issue: 2
  year: 2016
  ident: e_1_2_12_127_1
  article-title: Evaluating early interim 18F‐FDG PET/CT with Peking criteria for predicting the outcome of diffuse large B cell lymphoma
  publication-title: J Nucl Med
  contributor:
    fullname: Fan Y
– ident: e_1_2_12_48_1
  doi: 10.1093/annonc/mdw011
– ident: e_1_2_12_61_1
  doi: 10.1182/blood.V91.9.3340
– ident: e_1_2_12_3_1
  doi: 10.1200/JCO.2013.53.5229
– ident: e_1_2_12_82_1
  doi: 10.1007/s002590050275
– ident: e_1_2_12_5_1
  doi: 10.1200/JCO.2006.09.2403
– ident: e_1_2_12_116_1
  doi: 10.1038/sj.bmt.1705416
– ident: e_1_2_12_46_1
  doi: 10.1200/JCO.2009.22.4089
– ident: e_1_2_12_57_1
  doi: 10.1093/annonc/mdp030
– ident: e_1_2_12_45_1
  doi: 10.1007/s11307-009-0259-3
– ident: e_1_2_12_129_1
  doi: 10.1182/blood-2017-04-773838
– ident: e_1_2_12_66_1
  doi: 10.1023/A:1008327127033
– ident: e_1_2_12_144_1
  doi: 10.1053/j.semnuclmed.2019.06.005
– ident: e_1_2_12_70_1
  doi: 10.1046/j.1365-2141.2001.03147.x
– ident: e_1_2_12_104_1
  doi: 10.1093/annonc/mdg011
– ident: e_1_2_12_109_1
  doi: 10.1200/JCO.2011.38.2648
– ident: e_1_2_12_27_1
  doi: 10.1157/13112510
– ident: e_1_2_12_132_1
  doi: 10.1200/JCO.2016.66.9440
– volume: 91
  start-page: 522
  year: 2006
  ident: e_1_2_12_76_1
  article-title: 18F‐fluoro‐deoxyglucose positron emission tomography for post‐treatment evaluation of malignant lymphoma: a systematic review
  publication-title: Haematologica
  contributor:
    fullname: Zijlstra JM
– ident: e_1_2_12_81_1
  doi: 10.3109/10428190009113384
– ident: e_1_2_12_108_1
  doi: 10.1182/blood-2011-06-359943
– ident: e_1_2_12_84_1
  doi: 10.1097/MNM.0000000000000697
– ident: e_1_2_12_79_1
  doi: 10.1016/S1078-8174(99)90024-X
– ident: e_1_2_12_40_1
  doi: 10.1200/JCO.2012.43.0934
– ident: e_1_2_12_42_1
  doi: 10.1007/s00259-016-3390-9
– ident: e_1_2_12_111_1
  doi: 10.1007/s00277-010-1135-6
– ident: e_1_2_12_78_1
  doi: 10.1080/10428194.2019.1663422
– ident: e_1_2_12_29_1
  doi: 10.1007/s11547-008-0264-7
– volume: 47
  start-page: 1643
  year: 2006
  ident: e_1_2_12_50_1
  article-title: PET/CT in lymphoma: prospective study of enhanced full‐dose PET/CT versus unenhanced low‐dose PET/CT
  publication-title: J Nucl Med
  contributor:
    fullname: Rodriguez‐Vigil B
– ident: e_1_2_12_49_1
  doi: 10.1007/s00259-003-1375-y
– ident: e_1_2_12_54_1
  doi: 10.3109/10428194.2011.616613
– ident: e_1_2_12_83_1
  doi: 10.2967/jnumed.110.082586
– ident: e_1_2_12_100_1
  doi: 10.1016/j.bbmt.2008.11.026
– ident: e_1_2_12_125_1
  doi: 10.1182/blood-2016-05-716977
– ident: e_1_2_12_55_1
  doi: 10.1007/s00259-006-0238-8
– ident: e_1_2_12_74_1
  doi: 10.1002/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4
– ident: e_1_2_12_140_1
  doi: 10.2967/jnumed.120.242412
– ident: e_1_2_12_146_1
  doi: 10.1016/j.ymeth.2020.06.020
– ident: e_1_2_12_28_1
  doi: 10.1093/annonc/mdn282
– ident: e_1_2_12_30_1
  doi: 10.3816/CLM.2008.n.040
– ident: e_1_2_12_113_1
  doi: 10.1200/JCO.2009.26.5942
– ident: e_1_2_12_114_1
  doi: 10.1182/blood-2016-05-718528
– ident: e_1_2_12_93_1
  doi: 10.2967/jnumed.114.145326
– ident: e_1_2_12_112_1
  doi: 10.1007/s00277-012-1640-x
– ident: e_1_2_12_145_1
  doi: 10.1016/j.ymeth.2020.05.022
– ident: e_1_2_12_32_1
  doi: 10.1007/s00259-010-1539-5
– ident: e_1_2_12_47_1
  doi: 10.1093/annonc/mdq428
– ident: e_1_2_12_134_1
  doi: 10.1111/ejh.12268
– ident: e_1_2_12_101_1
  doi: 10.1093/annonc/mdi200
– ident: e_1_2_12_133_1
  doi: 10.1111/ejh.12467
– ident: e_1_2_12_106_1
  doi: 10.1007/s00259-011-1916-8
– ident: e_1_2_12_34_1
  doi: 10.3109/10428194.2013.767901
– volume: 47
  start-page: 1267
  year: 2006
  ident: e_1_2_12_122_1
  article-title: Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT
  publication-title: J Nucl Med
  contributor:
    fullname: Bruzzi JF
– ident: e_1_2_12_36_1
  doi: 10.2967/jnumed.112.110890
– ident: e_1_2_12_143_1
  doi: 10.1038/nrclinonc.2017.141
– ident: e_1_2_12_53_1
  doi: 10.1007/s00259-009-1377-5
– ident: e_1_2_12_96_1
  doi: 10.1182/blood-2017-02-766691
– ident: e_1_2_12_94_1
  doi: 10.1182/blood.V124.21.391.391
– ident: e_1_2_12_131_1
  doi: 10.1182/blood-2017-07-795476
– ident: e_1_2_12_25_1
  doi: 10.1093/annonc/mdj024
– ident: e_1_2_12_60_1
  doi: 10.1182/blood-2012-12-473389
– ident: e_1_2_12_110_1
  doi: 10.1182/blood-2011-02-336990
– ident: e_1_2_12_126_1
  doi: 10.1007/s12149-016-1092-9
– ident: e_1_2_12_10_1
  doi: 10.1182/asheducation-2006.1.259
– ident: e_1_2_12_33_1
  doi: 10.1093/annonc/mdt137
– ident: e_1_2_12_141_1
  doi: 10.1007/s00259-009-1297-4
– ident: e_1_2_12_73_1
  doi: 10.1046/j.1365-2141.2001.03169.x
– ident: e_1_2_12_15_1
  doi: 10.1023/A:1008368330519
– ident: e_1_2_12_31_1
  doi: 10.1016/j.ijrobp.2007.09.051
– ident: e_1_2_12_118_1
  doi: 10.1111/j.1365-2141.2010.08162.x
– ident: e_1_2_12_137_1
  doi: 10.1007/s00259-016-3315-7
– ident: e_1_2_12_147_1
  doi: 10.1148/radiol.2015150689
– ident: e_1_2_12_20_1
  doi: 10.1038/sj.bjc.6601561
– ident: e_1_2_12_105_1
  doi: 10.2967/jnumed.109.073197
– ident: e_1_2_12_136_1
  doi: 10.18632/oncotarget.20447
– volume: 8
  start-page: 1393
  year: 2001
  ident: e_1_2_12_72_1
  article-title: Comparison of 18FDG‐PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma
  publication-title: Oncol Rep
  contributor:
    fullname: Dittmann H
– ident: e_1_2_12_4_1
  doi: 10.1200/JCO.1999.17.4.1244
– ident: e_1_2_12_26_1
  doi: 10.1007/s00277-007-0356-9
– ident: e_1_2_12_85_1
  doi: 10.1056/NEJMoa1510093
– ident: e_1_2_12_124_1
  doi: 10.3109/10428194.2015.1099643
– ident: e_1_2_12_139_1
  doi: 10.1016/j.ejrad.2020.109301
– ident: e_1_2_12_130_1
  doi: 10.1182/blood-2017-06-788877
– ident: e_1_2_12_98_1
  doi: 10.1111/bjh.13036
– ident: e_1_2_12_99_1
  doi: 10.3109/10428194.2013.862242
– ident: e_1_2_12_107_1
  doi: 10.1002/cncr.25579
– ident: e_1_2_12_69_1
  doi: 10.1023/A:1008357126404
– ident: e_1_2_12_128_1
  doi: 10.1007/s00259-014-2715-9
SSID ssj0007253
Score 2.481305
SecondaryResourceType review_article
Snippet 18F‐fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is now an integral part of lymphoma staging and management. Because of...
F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is now an integral part of lymphoma staging and management. Because of its...
18 F‐fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is now an integral part of lymphoma staging and management. Because of...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 3727
SubjectTerms Chemotherapy
Classification
Computed tomography
Deauville 5‐point scale
diffuse large B‐cell lymphoma
end‐of‐treatment positron emission tomography/computed tomography
Fluorodeoxyglucose F18
follicular lymphoma
Glycolysis
Hodgkin lymphoma
Humans
interim positron emission tomography/computed tomography
Lugano classification
Lymphoma
Lymphoma - therapy
Lymphoma, Non-Hodgkin - therapy
Non-Hodgkin's lymphoma
non‐Hodgkin lymphoma
Oncology
Positron emission
Positron emission tomography
Positron Emission Tomography Computed Tomography - methods
positron emission tomography/computed tomography (PET/CT)
Precision medicine
Prognosis
Radiation
response‐adapted treatment
Tomography
Tumor Burden
Title Positron emission tomography/computed tomography in the management of Hodgkin and B‐cell non‐Hodgkin lymphoma: An update
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.33772
https://www.ncbi.nlm.nih.gov/pubmed/34286864
https://www.proquest.com/docview/2576679058
https://search.proquest.com/docview/2553821763
Volume 127
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Pb9MwFH-adkBcxgYMwjZkBKdJaZvYcZxpl1FRVUidULVKvaDIceyBRpOpaw-gHfgI-4x8Et7LvzKQkOBmxbYc-z2_P_bz7wG8USoRmYwHvhEJ91FDRb7SUewPhHNxZG1S5yKYnMvxTLyfR_MtOG3fwtT4EN2BG-2MSl7TBtfZTX8DGmoKs-xxjtYhCmBC0iOLaLrBjorDBoJyoPxI8HmHTRr2N13va6M_TMz7FmulckaP4GP7s3WkyVVvvcp65ttvOI7_O5td2GlsUXZWM88ebNniMTyYNLftT-D2A0V0LcuCUVI4OlZjq3LRYFz3TZ0PIv_lG_uMLT5Ztuhialjp2LjML6-wRhc5e_vj-x3dFbCiLLDYVn35ikxVLvQJOyvY-ppOIZ7CbPTuYjj2m2wNvuFIUV-gNOAO_TETc22SINPaukCHKpKx48LlCY8CY3MToFxDUWG4io2jp71KOpQqfB-2cWz7HBiapE6FmeFBlgsb5krShaceoMLVOTqkHrxuqZZe16AcaQ2_HKa0kGm1kB4ctgRNm415k5J_JQmUTHnwqqvGRaS568KWa2qDWgBdNck9eFYzQjcMR3dNKik8OK7I-Zfx0-H5cFqVXvxL4wN4GFLcDEXNRIewvVqu7REaPqvsZcXgPwF5hv-A
link.rule.ids 315,786,790,1382,27955,27956,46327,46751
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BkaCX8i6BAkZwQsruJn7E4VYWqgW6K1S10t4ix7FpVTaptruHIg78BH4jv4SZJJulICHBzYodWfZ4nh5_A_BC61TkKhmEVqQ8RA0lQ21kEg6E94l0Lm1qEYwnanQk3k_ltM3NobcwDT5EF3AjzqjlNTE4BaT7a9RQW9p5j3M0D6_CNeR3SXz55mCNHpXELQjlQIdS8GmHThr31_9e1kd_GJmXbdZa6ezdbCqrntdYhZRrctpbLvKe_fIbkuN_r-cWbLXmKNttzs9tuOLKO3B93F6434WvHympa16VjOrCUWSNLapZC3Pdt01JiOKXb-wERxw7NuvSaljl2agqPp1ijykL9vrHt-90XcDKqsTmquvzBZ6ramZesd2SLc8oEHEPjvbeHg5HYVuwIbQciRoKFAjco0tmE25sGuXGOB-ZWEuVeC58kXIZWVfYCEUbSgvLdWI9ve7VyqNg4fdhA-d2D4ChVep1nFse5YVwcaEV3XmaAepcU6BPGsDzFdmyswaXI2sQmOOMNjKrNzKAnRVFs5Y3zzNysRThkukAnnXduIm0dlO6akljUBGgt6Z4ANvNSeim4eixKa1EAC9rev5l_mw4GR7UrYf_Mvgp3Bgdjvez_XeTD49gM6Y0GkqikTuwsZgv3WO0gxb5k_q0_wRwCQOv
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVcWt5NW4oRnJCyu4kdx0Fc2i2r5dFVVVFpLyhy_KBVu8lqu3to1QM_gd_IL2Gc11KQkOBmxbYce8bzsMffALwSImEZj3u-Ygn1UUNFvpBR7PeYtXFkTFLlIjgc8eEJ-zCOxivwtnkLU-FDtAdubmeU8tpt8Km23SVoqMrVrEMpWod34C7jNHSu18HxEjwqDmsMyp7wI0bHLThp2F32va2O_rAxb5uspc4ZbMCX5m-rUJPzzmKeddT1b0CO_zud-7BeG6Nkr-KeB7Bi8oewdlhftz-CmyMX0jUrcuKywrlzNTIvJjXIdVdVCSH0L9_IGbY4NWTSBtWQwpJhob-eY43MNdn_8e27uywgeZFjsam6uEKuKibyDdnLyWLqjiEew8ng3ef-0K_TNfiKIkl9huKAWnTIVEylSoJMSmMDGYqIx5YyqxMaBcpoFaBgQ1mhqIiVdW97BbcoVugTWMWxzSYQtEmtCDNFg0wzE2rB3Y2n7KHGlRo9Ug9eNlRLpxUqR1rhL4epW8i0XEgPdhqCpvXOvEydg8UdKpnw4EVbjYvo5i5zUyxcG1QD6Ktx6sHTihHaYSj6a1xw5sHrkpx_GT_tj_rHZWnrXxo_h7Wjg0H66f3o4zbcC10MjYugiXZgdT5bmGdoBM2z3ZLXfwJsXQJe
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Positron+emission+tomography%2Fcomputed+tomography+in+the+management+of+Hodgkin+and+B-cell+non-Hodgkin+lymphoma%3A+An+update&rft.jtitle=Cancer&rft.au=Juweid%2C+Malik+E&rft.au=Mueller%2C+Marguerite&rft.au=Alhouri%2C+Abdullah&rft.au=A-Risheq%2C+M+Ziad&rft.date=2021-10-15&rft.eissn=1097-0142&rft.volume=127&rft.issue=20&rft.spage=3727&rft_id=info:doi/10.1002%2Fcncr.33772&rft_id=info%3Apmid%2F34286864&rft.externalDocID=34286864
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon